Long-Term Mortality Rates Elevated for Adolescent, Young Adult Leukemia Survivors
Survival for adolescent and young adult leukemia survivors remained below the general population at up to 30 years of follow-up.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
AYA Cancer Survivors Twice As Likely to Die From Second Cancer
The risk of dying from a subsequent primary cancer remained significantly elevated for 20 years or more for some patients.
Younger Cancer Patients May Be at High Risk of Death From COVID-19
Younger patients with cancer are “a high-risk population for poor outcomes from COVID-19,” according to researchers.
Frontline Daratumumab Improves Progression-Free Survival in High-Risk Multiple Myeloma
The addition of daratumumab resulted in a 41% reduction in the risk of disease progression or death.
Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma
Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes.
Omidubicel May Provide Long-Term Benefits With Allogeneic Transplantation for Hematologic Malignancies
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Molecular Profiling Can Guide Treatment After Recurrence in Young Cancer Patients
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
Response to CAR T-Cell Therapy Similar for Minority Patients
Progression-free and overall survival is similar for minority and nonminority patients receiving CAR T-cell therapy for non-Hodgkin lymphoma.
Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant
There was no significant difference in transplant-related mortality or overall survival.
Disparity in Access to CAR-T Therapy Associated With Lower Income Neighborhoods
Researchers sought to determine the reasons for a disparity in patients who receive CAR-T therapy.
Transplant Approach Produces “Promising” Long-Term Outcomes in Kids With Blood Cancers
The approach resulted in low rates of graft failure, viral infections, and relapse.
Idasanutlin Does Not Improve OS in Relapsed/Refractory Acute Myeloid Leukemia
There was no survival improvement with idasanutlin in the overall population or among patients with wild-type TP53.
Costs of Care and Complication Rates Among Patients With Hematologic Malignancies Undergoing Allo-HCT
Researchers sought to determine the costs of care and health resource use of patients with hematologic malignancies undergoing allo-HCT.
Responses to COVID-19 Vaccines Persist at 6 Months in Patients With Cancer
Researchers observed persistent anti-RBD antibodies at 6 months after the second dose of an mRNA COVID-19 vaccine and a 20-fold increase in anti-RBD antibodies after the third dose.
Risk of Neurologic AEs Lower With Immune Checkpoint Inhibitors Than With Other Cancer Therapies
The risk of neurologic adverse events was 41% lower in patients treated with immune checkpoint inhibitors than in patients who received another drug regimen or a placebo.
Lenalidomide Maintenance Superior to Bortezomib for Myeloma Patients With Abn1q
Among patients with Abn1q, those who received bortezomib-based maintenance had significantly worse progression-free survival and overall survival.
Moderna’s COVID-19 Vaccine May Be More Effective for Cancer Patients
Growing evidence suggests that patients with cancer have better responses to the Moderna COVID-19 vaccine than to the Pfizer-BioNTech vaccine.
NCCN: Most Cancer Patients Should Receive 5 Doses of an mRNA COVID-19 Vaccine
Most cancer patients should receive 3 primary doses of an mRNA COVID-19 vaccine and 2 booster doses, according to NCCN.
Results Support Allo-HSCT After CAR-T Failure in Large B-Cell Lymphoma
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.
Patterns of Resistance to CAR-T Therapy in Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
Loading... 
Loading...